Biocon Betting Big On Biosimilars As Profit Jumps
This article was originally published in PharmAsia News
Executive Summary
Biocon, India’s biggest biotechnology company, has just reported a 23% year-on-year jump in quarterly net profit, and says it has sharply boosted its research and development spend as it bets heavily on biosimilars.